CIMERLI .5 mg/.05mL
ranibizumab-eqrn · INJECTION, SOLUTION · Sandoz Inc
No Recall History
Plain English
CIMERLI is a injection, solution containing ranibizumab-eqrn at .5 mg/.05mL, taken intravitreal. Manufactured by Sandoz Inc.
Key Facts
- Brand Name
- CIMERLI
- Generic Name
- ranibizumab-eqrn
- NDC Code (Product)
61314-625- Manufacturer
- Sandoz Inc
- Strength
- .5 mg/.05mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- INTRAVITREAL
- Marketing Status
- Application #
- BLA761165
- Drug Class
- Vascular Endothelial Growth Factor Inhibitor [EPC]
- Marketing Start
- 12/12/2024
Recall History
No Recall HistoryFrequently Asked Questions
What is CIMERLI used for?
CIMERLI contains ranibizumab-eqrn. It is a injection, solution taken intravitreal. Consult your doctor for specific uses.
Is CIMERLI a controlled substance?
CIMERLI is not classified as a controlled substance by the DEA.
What is the generic name for CIMERLI?
The generic name for CIMERLI is ranibizumab-eqrn. There are no other listed brand versions of ranibizumab-eqrn.
What is the NDC code for CIMERLI .5 mg/.05mL?
The NDC (National Drug Code) for CIMERLI .5 mg/.05mL is 61314-625, listed by Sandoz Inc.
Other CIMERLI Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)